Study Shows Abortion Pill Could Prevent Breast Cancer

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.


A new study just released, reports the Washington Post, shows mifepristone, the active component of the abortion pill regimen RU-486, may stave off breast cancer. The research shows that BRCA1, a gene that causes breast cancer, actually accelerates the production of progesterone (a necessary hormone for pregnant women) in the body. Mifepristone blocks progesterone, and scientists discovered that it was very effective in shutting down cancer-causing genes in mice. It was actually 100% effective. Proponents of RU-486 are hoping that this new advancement will make the drug more available and therefore pave the way for women to use the pill for abortions. Scientists, though, are not yet convinced (and neither should you be– the long-term effects of RU-486 have not been studied because the drug is meant for one-time use only). There are concerns that long-term use of RU-486 by humans suppresses the immune system and scientists are looking into other progesterone blocking options. So, this is likely not, nor should it be hyped as, the pro-choice ticket to off-label cancer fighting use of RU-486, but, then again, it isn’t bad news for the much maligned abortion pill.

DECEMBER IS MAKE OR BREAK

A full one-third of our annual fundraising comes in this month alone. That’s risky, because a strong December means our newsroom is on the beat and reporting at full strength—but a weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again—any amount today.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

DECEMBER IS MAKE OR BREAK

A full one-third of our annual fundraising comes in this month alone. That’s risky, because a strong December means our newsroom is on the beat and reporting at full strength—but a weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again—any amount today.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate